OrbiMed and Maruho led a $200m Series A funding round in Upstream Bio.

OrbiMed, a healthcare-focused investment firm, and Maruho, a pharmaceutical company, led a $200m Series A funding round in Upstream Bio, a biotech company focused on inflammation, with participation from Access Biotechnology, Decheng Capital, HBM Healthcare Investments, TCG X, Omega Funds, Samsara BioCapital, and Altshuler Shaham Provident Funds. “Beyond asthma, we plan to pursue additional inflammatory diseases with UPB-101 and explore new additions to our pipeline where we believe we can deliver meaningful outcomes for patients. Upstream is thrilled that Dr. Aaron Deykin has joined the team to lead translational and development efforts. We will benefit from his deep experience in both drug development and clinical care for patients with asthma and other inflammatory diseases,” Samantha Truex, Upstream Bio CEO.